📈ICYMI we presented Preliminary Patient Demographics And Baseline Characteristics from Phase 3 Study #sunRIZE of Ersodetug for Hypoglycemia due to #CongenitalHI at #ENDO2025
📎 View the full poster here: bit.ly/416Pdt5
🙏Thank you to all who stopped by and engaged with us
#EndoSky #MedSky #Ph3 #RZLT

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INF... In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit…

Exciting #GIonc INFINITY ♾ #Ph2 trial

Neoadjuvant #IO in #stcsm #esocsm using #treme + #durva ~60% pCR

12m 🚫🔪#survival ~ 64%.

#Ph3 data needed, but organ preservation possible!

🔗: sciencedirect.com/science/arti...